IFNA1 and autoimmune disease: Despite their effective activity, the therapeutic applications of common IFN and PEG IFN are quite limited, and their use is prohibited in patients with uncompensated cirrhosis of the liver, acute exacerbation of chronic hepatitis, autoimmune disease, or mental illness.